Myocardial Infarction Market to Surpass US$ 2,714.8 Million by 2028

Global Myocardial Infarction Market, By Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics and Thrombolytics), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,816.8 million in 2021, and is expected to exhibit a CAGR of 5.9 %  during the forecast period (2021-2028).

Rising number of product approvals and launches is expected to drive the growth of the global myocardial infarction market during the forecast period. For instance, on February 21, 2020, Eli Lilly and Company, a global healthcare leader, announced that the U. S. Food and Drug Administration (FDA) had approved Trulicity (dulaglutide) which is indicated for the reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

Increase in number of awareness programs by philanthropic organizations is expected to propel the growth of the global myocardial infarction market during the forecast period. For instance, on January 26, 2021, The Centers for Disease Control and Prevention (CDC Foundation) launched a new public-private coalition for the national campaign to fight cardiovascular disease. The Million Hearts Initiative launched by CDC aims to prevent at least one million heart attacks, strokes, and cardiovascular events by 2022. The national campaign will focus on assisting more people in understanding their personal risk for heart disease and stroke, believing in their ability to change it, and taking steps to reduce their risks.

Global Myocardial Infarction Market - Impact of Coronavirus (COVID – 19) Pandemic

The COVID-19 pandemic has affected several markets across the globe and is expected to hamper the global myocardial infarction market. The COVID-19 pandemic has affected the demand and supply of healthcare products in three main ways; by directly affecting the production and demand; by creating disruptions in distribution channels; and due to its financial impact on firms and financial markets. Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global myocardial infarction market during the forecast period, owing to the decline in hospitalization rates due to heart attack. For instance, according to an article published in American College of Cardiology on August 24, 2020, multiple studies in the U.S. and Europe were conducted and it was found that hospitalization rates for acute myocardial infarction (AMI) have decreased and case fatality rates for patients hospitalized with AMI have increased during the COVID-19 pandemic. Healthcare professionals must work together to ensure that patients who exhibit signs or symptoms of AMI seek immediate medical attention in order to avoid negative outcomes during the pandemic and beyond.

However, impact of the coronavirus (COVID-19) pandemic might drive the growth of the global myocardial infarction market during the forecast period, owing to the increase in post-COVID-19 complications related to cardiac disorders. Although, viral pneumonia is the most common clinical manifestation of COVID-19. COVID-19 can also cause cardiovascular problems such as myocardial infarction and arrhythmias. For instance, in July 2020, according to review article published in Nature Review Cardiology, in early studies conducted in China in March-April 2020, 7–20 % with COVID-19 experienced acute myocardial injury, as evidenced by elevated levels of cardiac biomarkers or electrocardiogram abnormalities. In addition, a multicenter cohort study conducted in Wuhan, China, in March-April 2020, 33 patients (17 %) with COVID-19 experienced acute cardiac injury, 32 of whom died.

Browse 33 Market Data Tables and 25 Figures spread through 167 Pages and in-depth TOC on Global Myocardial Infarction Market, By Drug Class (Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, and Thrombolytics), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Myocardial Infarction market, click the link below:

 https://www.coherentmarketinsights.com/market-insight/myocardial-infarction-market-4585

Key Takeaways of the Global Myocardial Infarction Market:

• The global myocardial infarction market is expected to exhibit a CAGR of 5.9 % over the forecast period (2021-2028). Rising acquisitions and contract agreements among the market players is expected to boost the growth of global myocardial infarction market over the forecast period (2021-2028). For instance, on November 19, 2019, Antares Pharma, Inc., a combination drug device company, announced that it had entered into an international agreement with Idorsia Pharmaceuticals Ltd., a biopharmaceutical organization based in Europe, for SELATOGREL, Idorsia's potent, fast-appearing, and highly selective P2Y12 receptor antagonist under development, that will be combined with the Antares’s subcutaneous QuickShot auto injector to create a novel drug-tool product. SELATOGREL is a new chemical entity (NCE) which is in Phase 3 registration for the treatment of a suspected acute myocardial infarction (AMI) in adult patients.
• Some of the major players operating in the global myocardial infarction market include Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA.